propranolol has been researched along with Colorectal Cancer in 9 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the model of multicellular spheroids formed by colorectal cancer cells we described a crosstalk between beta-blockade by propranolol and tumour microenvironment." | 7.96 | Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells. ( Barathova, M; Belvoncikova, P; Csaderova, L; Grossmannova, K; Kubasova, V; Pastorek, J; Simko, V; Skubla, R, 2020) |
| " In the model of multicellular spheroids formed by colorectal cancer cells we described a crosstalk between beta-blockade by propranolol and tumour microenvironment." | 3.96 | Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells. ( Barathova, M; Belvoncikova, P; Csaderova, L; Grossmannova, K; Kubasova, V; Pastorek, J; Simko, V; Skubla, R, 2020) |
| "Using as in vitro models the colorectal cancer cell lines HCT116, HT29, and CT26, and as triple-negative breast cancer models the 4T1, M-406, and MDA-MB-231 cell lines, we evaluated the effect of the drugs combination on the viability, apoptosis, clonogenicity, and cellular migratory capacity." | 1.91 | Potential effect of chloroquine and propranolol combination to treat colorectal and triple-negative breast cancers. ( Anselmino, LE; Baglioni, MV; Menacho-Márquez, M; Reynoso, G; Rico, MJ; Rozados, VR; Scharovsky, OG, 2023) |
| "Patients with a colorectal cancer- specific death (data from the Office of National Statistics death registration system) were matched to five controls." | 1.39 | β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. ( Cardwell, CR; Hicks, BM; Hughes, CM; Murray, LJ; Powe, DG, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, Y | 1 |
| Liu, Y | 1 |
| Gao, Z | 1 |
| Jing, D | 1 |
| Bi, R | 1 |
| Cui, X | 1 |
| Cao, Q | 1 |
| Zhao, Q | 1 |
| Gao, R | 1 |
| Su, Y | 1 |
| Liu, S | 1 |
| Zhao, M | 1 |
| Yang, Y | 1 |
| Chen, A | 1 |
| Dai, B | 1 |
| Gao, X | 1 |
| Anselmino, LE | 2 |
| Baglioni, MV | 2 |
| Reynoso, G | 1 |
| Rozados, VR | 1 |
| Scharovsky, OG | 2 |
| Rico, MJ | 2 |
| Menacho-Márquez, M | 1 |
| Barathova, M | 1 |
| Grossmannova, K | 1 |
| Belvoncikova, P | 1 |
| Kubasova, V | 1 |
| Simko, V | 1 |
| Skubla, R | 1 |
| Csaderova, L | 1 |
| Pastorek, J | 1 |
| Malizia, F | 1 |
| Laluce, NC | 1 |
| Etichetti, CB | 1 |
| Marignac, VLM | 1 |
| Rozados, V | 1 |
| Girardini, J | 1 |
| Menacho Márquez, M | 1 |
| Lin, Q | 1 |
| Wang, F | 1 |
| Yang, R | 1 |
| Zheng, X | 1 |
| Gao, H | 1 |
| Zhang, P | 1 |
| Hicks, BM | 1 |
| Murray, LJ | 1 |
| Powe, DG | 1 |
| Hughes, CM | 1 |
| Cardwell, CR | 1 |
| Coelho, M | 1 |
| Moz, M | 1 |
| Correia, G | 1 |
| Teixeira, A | 1 |
| Medeiros, R | 1 |
| Ribeiro, L | 1 |
| Chin, CC | 1 |
| Li, JM | 1 |
| Lee, KF | 1 |
| Huang, YC | 1 |
| Wang, KC | 1 |
| Lai, HC | 1 |
| Cheng, CC | 1 |
| Kuo, YH | 1 |
| Shi, CS | 1 |
| Zhang, J | 1 |
| Deng, YT | 1 |
| Liu, J | 1 |
| Wang, YQ | 1 |
| Yi, TW | 1 |
| Huang, BY | 1 |
| He, SS | 1 |
| Zheng, B | 1 |
| Jiang, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial.[NCT00888797] | Phase 3 | 400 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for propranolol and Colorectal Cancer
| Article | Year |
|---|---|
Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer.
Topics: Adrenergic beta-Antagonists; Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colorectal Neopl | 2023 |
Potential effect of chloroquine and propranolol combination to treat colorectal and triple-negative breast cancers.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chloroquine; Colorectal Neoplasms; Humans; | 2023 |
Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells.
Topics: Adrenergic beta-Antagonists; Antigens, Neoplasm; Carbonic Anhydrase IX; Cell Hypoxia; Cell Line, Tum | 2020 |
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemother | 2021 |
Effect of chronic restraint stress on human colorectal carcinoma growth in mice.
Topics: Adrenergic Antagonists; Animals; Atenolol; Cell Proliferation; Colorectal Neoplasms; Epinephrine; Ge | 2013 |
β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Case | 2013 |
Antiproliferative effects of β-blockers on human colorectal cancer cells.
Topics: Adenocarcinoma; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Atenolol; Carbazoles; Carvedi | 2015 |
Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Animals; Apoptosis; | 2016 |
Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro.
Topics: Adrenergic beta-Antagonists; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Cyclic AMP; Epit | 2016 |